Targeted Therapy Market
Targeted therapy is used individually and in combination with other treatments, such as traditional or standard chemotherapy, surgery, or radiation therapy. It is the foundation of precision medicine. Targeted therapies are divided into two classes such as small molecule medicines and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells. Monoclonal antibodies, also known as therapeutic antibodies, are proteins produced in the lab. Most types of targeted therapies help to treat cancer by interfering with specific proteins that help tumors grow and spread throughout the body. They treat cancer in many ways such as helps the immune system destroy cancer cells, stop cancer cells from growing, stop signals that help form blood vessels, cause cancer cell death, deliver cell-killing substances to cancer cells, starve cancer of the hormones it needs to grow. Targeted therapies is approved by the U.S. Food and Drug Administration for various types of cancers. This offers significant benefits to treat the cancer such as alter proteins within cancer cells that cause those cells to die, prevent new blood vessels from forming, which cuts off blood supply to tumor, and others. One of the major advantage of targeted therapy is it helps to reduce cancer treatment-related side effects and improved outcomes.
Market Dynamics
Increase in awareness regarding the advanced therapeutics to treat cancer leads to facilitate drug development in precision oncology is likely expected to boost the growth of market. For instance, in May 2021, the U.S. Food and Drug Administration had approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer. Furthermore, key players operating in the market are engaged in focusing on expanding the products pipeline and thereby strengthening the market position. This in turn to drive the growth of market. For instance, Xilio Therapeutics, a biotechnology company entered into a clinical trial collaboration and supply agreement with Merck to evaluate XTX101, Xilio’s engineered tumor-selective Fc-enhanced, anti-CTLA-4 monoclonal antibody (mAb) product candidate, in combination with KEYTRUDA.
Key features of the study
Market Segmentation
Table of Contents
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
